ArticleDiscover oncology2025
Ethyl β-carboline-3-carboxylate targets PRDX5/c-Jun axis for novel therapeutic strategy against cervical cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCervical cancer remains a significant global health challenge, with conventional therapies often proving inadequate due to treatment resistance and adverse effects. This study investigates the therapeutic potential of ethyl β-carboline-3-carboxylate (β-CCE) in cervical cancer and elucidates its molecular mechanism through peroxiredoxin 5 (PRDX5) modulation.
methodsWestern blot assay were performed to asses the expression of protein levels; The cellular and mitochondrial ROS and mithochondrial membrane potential were observed with fluorescence microscopy; Bioinformatics analysis were used to check the expression levels of PRDX5 and JUN family proteins and prognosis analysis in cervical cancer; Transcriptome analysis was performed to analyse the gene expression levels between mock and shPRDX 5 cells; Serum TNF-α and INF-γ levels were detected by ELISA kits; HE staining analysis were performed to check the organ histopathological changes in mice.
resultsThis effect is mediated through activation of the MAPK signaling cascade, particularly involving P38, ERK, and JNK pathways. Notably, β-CCE treatment promotes apoptosis through c-Jun up-regulation, with PRDX5 knockdown enhancing this effect while its overexpression provides protection. In xenograft mouse models, β-CCE treatment significantly suppressed tumor growth and enhanced anti-tumor immune responses, particularly in PRDX5-depleted conditions, without apparent systemic toxicity. The therapeutic efficacy was evidenced by reduced tumor volume (65.3%) and elevated levels of immunological markers (IFN-γ and TNF-α).
conclusionThese findings establish PRDX5 as a critical therapeutic target in cervical cancer and demonstrate β-CCE potential as a novel treatment strategy through its dual mechanism of direct tumor cell apoptosis and immune response modulation. Our study provides compelling evidence for the development of PRDX5-targeted therapies using β-CCE as a promising therapeutic agent for cervical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.